The die has been cast - Opdivo (nivolumab) will be re-priced before the next FY2018 drug price revision. Now the question is how much lower? When? And, how will it affect the price-setting of its archrival Keytruda (pembrolizumab)? Tug-of-War over…
To read the full story
Related Article
- Shiozaki Does Not Rule Out Price Cut of Over 25% for Opdivo
October 27, 2016
- Keytruda’s November Listing Skip Likely amid Opdivo Re-Pricing Fuss
October 24, 2016
COMMENTARY
- A Turning Point for Pharma? Chuikyo Reform Could Open Door to Greater Industry Role
July 13, 2026
- DORA Use Could Expand as Japan Opens Door to “Sleep Disorders” Specialty
July 6, 2026
- New Generic Listings Plunge, Industry Heads for a Shakeout
July 1, 2026
- Adaptation, Diversification Key as Drug Wholesalers Face Profit Squeeze
June 16, 2026
- 20 Years at a Glance: Overseas Sales Surge at Japan Pharma, but R&D Investments Lag
June 9, 2026
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…





